Thompson Siegel & Walmsley LLC Biogen Inc. Transaction History

Thompson Siegel & Walmsley LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	SELL	$275.25 - $318.06 $13,212 - $15,266	-48 Reduced 10.88%	393 $112,000
Q4 2022 Feb 10, 2023	BUY	$252.44 - $306.72 $111,326 - $135,263	441 New	441 $122,000
Q4 2021 Feb 09, 2022	SELL	$223.92 - $287.77 $1,119 - $1,438	-5 Reduced 1.12%	441 $106,000
Q2 2021 Aug 09, 2021	SELL	$259.0 - $414.71 $3,885 - $6,220	-15 Reduced 3.25%	446 $154,000
Q1 2021 May 07, 2021	SELL	$242.95 - $284.63 $15,062 - $17,647	-62 Reduced 11.85%	461 $129,000
Q4 2020 Feb 08, 2021	SELL	$236.26 - $355.63 $3.58 Million - $5.39 Million	-15,155 Reduced 96.66%	523 $128,000
Q3 2020 Nov 12, 2020	SELL	$264.77 - $305.71 $480,822 - $555,169	-1,816 Reduced 10.38%	15,678 $4.45 Million
Q2 2020 Aug 11, 2020	BUY	$258.66 - $342.55 $691,656 - $915,978	2,674 Added 18.04%	17,494 $4.68 Million
Q1 2020 May 12, 2020	BUY	$268.85 - $341.04 $3.87 Million - $4.92 Million	14,412 Added 3532.35%	14,820 $4.69 Million
Q4 2019 Feb 07, 2020	BUY	$220.06 - $304.07 $2,640 - $3,648	12 Added 3.03%	408 $121,000
Q1 2018 May 08, 2018	SELL	$260.13 - $367.91 $34,337 - $48,564	-132 Reduced 25.0%	396 $108,000
Q2 2017 Aug 09, 2017	BUY	N/A	528	528 $143,000

1,032

126M

1.13M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $21.4B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Thompson Siegel & Walmsley LLC, based on Form 13F filings with the SEC.

Stay updated on Thompson Siegel & Walmsley LLC with notifications on news.